Damora Therapeutics, Inc. - Ordinary Shares (DMRA)
21.86
-1.08 (-4.71%)
NASDAQ · Last Trade: Nov 5th, 8:49 PM EST
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surgefool.com
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Via The Motley Fool · May 30, 2026